 |
| Dr. Raymond Townsend, M.D., Director of the Hypertension Program
at the University
of Pennsylvania |
Dr. Raymond R. Townsend is trained in Internal Medicine, Nephrology, Clinical Pharmacology and Hypertension with certification in all four areas. He is currently the Director of the Hypertension Program at the University of Pennsylvania in Philadelphia, Pennsylvania, USA. His current research interests include insulin resistance, hypertension treatments (allopathic and natural) and factors involved in the progression of kidney failure.
Q. What is C12 PEPTION?
A. C12 PEPTION is the brand name of an all-natural ingredient (C12 Peptide) derived from the milk protein casein using natural enzymes that reduce casein into small fragments (peptides). These peptides derived from casein have been shown to be effective in maintaining blood pressures in a normal range.
Q. How does C12 PEPTION work?
A. C12 PEPTION works with the body's natural enzymatic processes and inhibits the body's Angiotensin Converting Enzyme (ACE)—the key enzyme in the regulation of blood pressure. This is vital because ACE catalyzes the conversion of Angiotensin I into Angiotensin II, a compound shown to cause the contraction of blood vessels (vaso-constriction). C12 PEPTION will work with the body's natural processes to inhibit this conversion.
Q. Is it safe and natural?
A. C12 PEPTION has proven itself to be safe and effective in human clinical trials. The many benefits were demonstrated in studies at the University of Pennsylvania (Philadelphia) and these studies confirmed earlier results obtained in Japan.
|
100% Customer Satisfaction Guarantee
C12 Peptide featuring C12 Peption™ was the subject of a study in Japan with a group of 18 volunteers with mild hypertension. The study consisted of a 2 week observational pre-treatment period prior to the beginning of a 4 week treatment period. During the treatment period, subjects were given a beverage containing 100 mg of C12 Peptide twice per day after breakfast and before supper. No particular dietary restriction was imposed on the subjects. After the 4 week treatment period, the subjects were observed for an additional 2 week post-treatment period. During all phases of the study, blood pressure and pulse rates were measured and recorded once each week. The results showed a reduction in average systolic and diastolic blood pressure rates at two weeks, with additional reductions in both at the end of 4 weeks, but during the 2 week post-treatment period, the average blood pressure levels tended to return toward the levels during the observational pre-treatment period. See graph.
